Celularity CEO Comments on Centers for Medicare & Medicaid Services Withdrawal of Skin Substitute Local Coverage Determinations
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
November 26, 2025 19:00 ET | Source: HUTCHMED (China) Limited HONG KONG…
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
September 04, 2025 20:00 ET | Source: HUTCHMED (China) Limited HONG KONG…
HUTCHMED to Announce 2025 Half-Year Financial Results
July 03, 2025 04:30 ET | Source: HUTCHMED (China) Limited HONG KONG…
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
June 18, 2025 16:30 ET | Source: Cellectar Biosciences, Inc. FLORHAM PARK,…
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE…
Celularity Receives Nasdaq Notice Regarding Form 10-Q
May 30, 2025 17:30 ET | Source: Celularity Inc. FLORHAM PARK, N.J.,…